Ventana is pleased to announce the launch of the INFORM™ HER2 Silver in situ Hybridization (SISH) technology for use in the European, Canadian, Asian, and Australian markets. HER2 SISH release is expected early 2008 for use in the United States pending FDA approval.

HER2 SISH is the only fully automated silver in situ hybridization assay for HER2 gene and Chromosome 17 (Chr17) detection. Precise chromogenic signals are detected through the use of advanced silver deposition technology. The HER2 SISH method is performed in less than half the time required for current FDA approved fluorescent technologies thereby allowing for same day results. Results and morphological significance can be easily interpreted by pathologists using conventional bright field microscopy.